Sintilimab Combined with Immunochemotherapy in Primary CNS Lymphoma: Phase 2 Study
Key Findings:
– Sintilimab combined with high-dose methotrexate, temozolomide, and rituximab showed a 96.3% overall response rate in newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
– The treatment regimen demonstrated high efficacy and tolerability, with 25 complete responses out of 27 evaluable patients.
– Patients showed promising progression-free survival and overall survival rates at a median follow-up of 24.4 months.
– Baseline levels of certain biomarkers in cerebrospinal fluid were identified as potential predictors of progression-free survival.
– Genetic analysis revealed different mutation patterns associated with clinical benefit, providing insights for further investigation.
Practical Solutions and Value:
– The SMTR regimen offers a highly effective and well-tolerated treatment option for newly diagnosed PCNSL patients.
– Identification of predictive biomarkers and genetic mutation patterns can guide personalized treatment approaches.
– These findings support the need for further research into the potential of this combination therapy in PCNSL treatment.
AI-Driven Clinical Support:
– DocSym, our AI-driven platform, consolidates clinical standards and research, providing a comprehensive knowledge base for clinicians.
– Our mobile apps support scheduling, treatment monitoring, and telemedicine, enhancing patient care and digital service expansion.
– AI integration can streamline clinic workflows, improve patient outcomes, and reduce paper-based routines.
Learn more about our AI-driven solutions at aidevmd.com.
